Interaction of Huntington Disease Protein with Transcriptional Activator Sp1

AUTOR(ES)

Li, Shi-Hua

FONTE

American Society for Microbiology

RESUMO

Polyglutamine expansion causes Huntington disease (HD) and at least seven other neurodegenerative diseases. In HD, N-terminal fragments of huntingtin with an expanded glutamine tract are able to aggregate and accumulate in the nucleus. Although intranuclear huntingtin affects the expression of numerous genes, the mechanism of this nuclear effect is unknown. Here we report that huntingtin interacts with Sp1, a transcription factor that binds to GC-rich elements in certain promoters and activates transcription of the corresponding genes. In vitro binding and immunoprecipitation assays show that polyglutamine expansion enhances the interaction of N-terminal huntingtin with Sp1. In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin. Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells. Overexpression of Sp1 reduces the cellular toxicity and neuritic extension defects caused by intranuclear mutant huntingtin. These findings suggest that the soluble form of mutant huntingtin in the nucleus may cause cellular dysfunction by binding to Sp1 and thus reducing the expression of Sp1-regulated genes.

Documentos Relacionados

• ZBP-89 represses vimentin gene transcription by interacting with the transcriptional activator, Sp1
• Transcriptional Regulation of BACE1, the β-Amyloid Precursor Protein β-Secretase, by Sp1
• Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein.
• Low pH enhances Sp1 DNA binding activity and interaction with TBP
• Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter.